In this section of the General Tradeshow News Site, you'll find event-related news releases from PR Newswire. The releases are listed in chronological order and are archived by month and year.
BLINCYTO, Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in US and EU, Shows Benefit in Phase 2 Trial in Patients With Persistent or Recurrent Minimal Residual Disease (MRD)
Phase 3 IMBRUVICA monotherapy results in mantle cell lymphoma published online in The Lancet and simultaneously presented at the 2015 American Society of Hematology (ASH) Meeting